TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15512856
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg PAS
Study: 15512856
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg PAS
Study: 11158017
Drug: Hormonal replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal replacement therapy (estradiol valerate at 2 mg/day for 11 days and cyproterone acetate at 1 mg/day for 10 days; group C)
Study: 11158017
Drug: Estradiol alone
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol alone (patches with E(2) release of 50 microg/24 h; group B)
Study: 8002638
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group A)
Study: 2852540
Drug: Fibre yoghurt
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre yoghurt (150 ml containing lactitol, guar gum, and wheat bran) twice daily for 2 weeks
Study: 2852540
Drug: Control yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control yoghurt (150 ml without lactitol, guar gum, or wheat bran) twice daily for 2 weeks
Study: 28211169
Drug: DS-1040 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1040 (0.1 mg to 40 mg, administered as a 0.5-h intravenous infusion or as a 24-h continuous infusion)
Study: 23472879
Drug: NO₂⁻ infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO₂⁻ infusion (0.31 to 7.8 μmol·min⁻¹)
Study: 23472879
Drug: NO₂⁻ infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO₂⁻ infusion
Study: 19085579
Drug: Ciclesonide 640
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 640 micro g/day
Study: 19085579
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 640 micro g/day
Study: 10196018
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of antioxidant vitamin supplements
Study: 7757360
Drug: Immunomodulating agents
Normalized name: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulating agents (specific agents not detailed)
Study: 2184637
Drug: Vincristine (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (0.02 to 0.04 mg/kg)
Study: 2184637
Drug: Vinblastine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine (0.1 to 0.2 mg/kg)
Study: 760738
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg intravenous injection
Study: 760738
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg oral dose
Study: 760738
Drug: Cimetidine treatment
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine treatment (various doses)
Study: 27873094
Drug: EBR (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBR (50 mg) + GZR (50 mg) for 12 weeks
Study: 27873094
Drug: EBR (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBR (50 mg) + GZR (100 mg) for 12 weeks
Study: 27873094
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with EBR (50 mg) + GZR (100 mg) for 12 weeks (noncirrhotic patients)
Study: 27873094
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with EBR (50 mg) + GZR (100 mg) for 12 weeks (cirrhotic patients)
Study: 27873094
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment with EBR (50 mg) + GZR (100 mg) for 12 weeks (noncirrhotic patients)
Study: 25191890
Drug: Zirconia implants
Normalized name: zirconium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zirconia implants (test group)
Study: 25191890
Drug: Titanium implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium implants (control group)
Study: 7988012
Drug: Thyroid hormones
Normalized name: Thyroid hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormones
Study: 7988012
Drug: Post-load plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-load plasma glucose and insulin concentrations
Study: 2743469
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline infusion
Study: 31058633
Drug: Poor oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor oral hygiene
Study: 25885106
Drug: liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.2 mg QD sc
Study: 25885106
Drug: metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 1000 mg BID po
Study: 23612494
Drug: Intranasal Botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Botulinum Toxin‐A (75IU Dysport®)
Study: 21197615
Drug: Oxazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (20 mg p.o.)
Study: 17531691
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (extended study period)
Study: 15364759
Drug: nCPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP therapy (during application)
Study: 15364759
Drug: nCPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP therapy (before application)
Study: 11589843
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine 5 mg
Study: 9647968
Drug: Esterified estrogens
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified estrogens plus methyltestosterone for four and eight weeks of daily drug administration
Study: 9647968
Drug: Esterified estrogens
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified estrogens alone for four and eight weeks of daily drug administration
Study: 7991990
Drug: c-erbB-2 protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: c-erbB-2 protein levels during chemotherapy in recurrent or inoperable metastatic disease
Study: 2647667
Drug: Relaxation training
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation training (stepwise relaxation/hypnosis/autogenic training/cognitive behavior therapy)
Study: 2647667
Drug: Micro-electrical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-electrical therapy (TENS/Neurotransmitter Modulation)
Study: 2647667
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment (combination of any of the above two treatments)
Study: 2647667
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term intervention (15 or less treatments)
Study: 2647667
Drug: Long term
Normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term intervention (greater than 15 treatments)
Study: 31955968
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine combined with 0.3 μg/mL sufentanil
Study: 31745043
Drug: Mouthwash containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash containing essential oils and curcumin (MEC) as an adjunct to scaling and root planing (SRP)
Study: 31745043
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine mouthwash as an adjunct to scaling and root planing (SRP)
Study: 24668575
Drug: Intrathecal 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 0.5% isobaric levobupivacaine with 25 mcg fentanyl
Study: 17129547
Drug: Prednisone 40
Normalized name: prednisone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 40 mg daily for 4 weeks, followed by 2 weeks without treatment, and lamivudine 150 mg daily for 4 weeks; followed by lamivudine plus interferon alfa 2b (10 MIU every other day) for 24 weeks and continuous lamivudine 150 mg daily to complete 58 weeks
Study: 17129547
Drug: Lamivudine 150
Normalized name: lamivudine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 150 mg daily for 4 weeks plus interferon alfa 2b (10 MIU every other day) for 24 weeks, without prednisone
Study: 15361771
Drug: Daily fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily fish meal
Study: 9309708
Drug: Dextromethorphan (36‐38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (36‐38 mg/kg/day)
Study: 3739805
Drug: Medium drinkers
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium drinkers consuming an experimental dose similar to their usual dose
Study: 3739805
Drug: Heavy drinkers
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy drinkers consuming a dose lower than their usual dose
Study: 22658300
Drug: Left atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left atrial volume index (LAVI) > 32 ml/m(2)
Study: 20886787
Drug: Medication (Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Sodium Hyaluronate eye drops, 1 drop three times per day)
Study: 10721929
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron as ferrous sulfate daily from Monday to Friday
Study: 10721929
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron as ferrous sulfate 2 d/wk and 3 d placebo (intermittent)
Study: 9188929
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (200 micrograms once daily for 4 weeks)
Study: 9188929
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg once daily for 4 weeks)
Study: 3549875
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg atropine
Study: 26331692
Drug: GW406381 (COX-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW406381 (COX-2 inhibitor)
Study: 20457702
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment (no identified aetiology)
Study: 18971490
Drug: Early insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early insulin therapy (continuous infusion of insulin at a dose of 0.05 U/kg/hour with 20% dextrose support)
Study: 24281139
Drug: Early insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early insulin therapy
Study: 12634885
Drug: Antiarrhythmic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic therapy (e.g. amiodarone)
Study: 12634885
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy and angiotensin converting enzyme inhibitors
Study: 9684946
Drug: 300 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/kg Hypericum extract (WS 5572, containing 5% hyperforin) in rats
Study: 9684946
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg hypericum extracts (14.8 mg hyperforin) in human volunteers
Study: 9684946
Drug: Repeated dose
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dose of 3 x 300 mg/day of the extract in human volunteers
Study: 9684946
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of 900 or 1200 mg of extract in human volunteers
Study: 2965126
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg teicoplanin given intravenously on induction of anaesthesia
Study: 2965126
Drug: Three perioperative
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three perioperative injections of cefuroxime
Study: 26970533
Drug: Maintenance Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance Rituximab (MR) - single dose rituximab every 3 months until treatment failure
Study: 26970533
Drug: Retreatment Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Retreatment Rituximab (RR) - rituximab weekly for 4 weeks at the time of each progression until treatment failure
Study: 25500487
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg canagliflozin
Study: 25802729
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg canagliflozin
Study: 16828533
Drug: Propranolol HCl
Normalized name: propranolol HCl
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol HCl administered before acquisition
Study: 16828533
Drug: Propranolol HCl
Normalized name: propranolol HCl
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol HCl administered following extinction trials
Study: 15272106
Drug: Paroxetine (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (selective serotonin reuptake inhibitor antidepressant)
Study: 11383378
Drug: Rosuvastatin (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (1, 2.5, 5, 10, 20, 40, and 80 mg/day)
Study: 9241125
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg)
Study: 9241125
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Probucol + Multivitamins)
Study: 9241125
Drug: Multivitamins (30,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamins (30,000 IU beta carotene, 500 mg vitamin C, 700 IU vitamin E)
Study: 30567603
Drug: Twice-daily text-message
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily text-message reminders on case management of malaria
Study: 30567603
Drug: Twice-daily text-message
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily text-message reminders on case management of malaria, pneumonia, and diarrhoea
Study: 25058346
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg BID plus standard dose of weekly paclitaxel
Study: 15207761
Drug: ibandronate therapy
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibandronate therapy (6 or 12 mg)
Study: 2857361
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen at 2 atmospheres absolute for 90 min daily for a total of 20 exposures
Study: 27347862
Drug: Hip-focused muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hip-focused muscle strengthening treatment program
Study: 27347862
Drug: Knee-focused muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee-focused muscle strengthening treatment program
Study: 18814197
Drug: Caregiver education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver education and training intervention delivered over five, weekly, half‐hour sessions consisting of assessment, basic education about dementia, and training regarding specific problem behaviors.
Study: 16484875
Drug: Rofecoxib 12.5
Normalized name: rofecoxib 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 12.5 mg per day
Study: 16484875
Drug: Nabumetone 500
Normalized name: nabumetone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone 500 mg twice a day
Study: 12941090
Drug: 2% hydroquinone‐cyclodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% hydroquinone‐cyclodextrin formulation applied once daily for 2 months
Study: 10711913
Drug: Lamotrigine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (300 mg by mouth)
Study: 31246555
Drug: Concurrent exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent exercise at the same intensities as RHG and cycling
Study: 27008287
Drug: C-arm guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-arm guided epidural injection of local anesthetic and corticosteroid
Study: 17366252
Drug: More problems
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More problems with drugs
Study: 16295212
Drug: Melatonin 0.3
Normalized name: melatonin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0.3 mg
Study: 16295212
Drug: Melatonin 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3.0 mg
Study: 11600532
Drug: Melatonin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0.1 mg
Study: 22949577
Drug: osmotic‐release oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: osmotic‐release oral system methylphenidate (OROS‐MPH) + transdermal nicotine replacement + brief cessation counseling
Study: 22949577
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + transdermal nicotine replacement + brief cessation counseling
Study: 18791983
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group psychotherapy in combination with open methylphenidate treatment (Medikinet retard ®) titrated upward individually until the maximum dose of 1.3 mg/kg/day
Study: 16548956
Drug: Diclofenac‐Hand group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac‐Hand group (diclofenac transdermal patch on the dorsum of hand and placebo patch on the buttock)
Study: 16548956
Drug: Diclofenac‐Buttock group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac‐Buttock group (placebo patch on the dorsum of the hand and diclofenac transdermal patch on the buttock)
Study: 16548956
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo adhesive patch on both the dorsum of hand and the buttock)
Study: 2908720
Drug: celiprolol 400
Normalized name: celiprolol 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celiprolol 400 mg
Study: 2908720
Drug: enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 20 mg
Study: 30787294
Drug: RV144 HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV144 HIV vaccine
Study: 27468593
Drug: Ketoprofen (1.60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (1.60 mg/mL)
Study: 25245482
Drug: Traditional Swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Swallowing (TS) therapy
Study: 25245482
Drug: Combined NMES/TS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined NMES/TS therapy
Study: 25245482
Drug: Oropharyngeal neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal neuromuscular electrical stimulation (NMES) therapy
Study: 22989795
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n=81)
Study: 17265406
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for bacterial pneumonia (specifics not provided)
Study: 12428086
Drug: DX-9065a (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DX-9065a (1 mg bolus + 0.25 mg/h x 2 h, followed by 1 mg bolus + 0.625 mg/h x 2 h, and a final 1 mg bolus + 1.25 mg/h x 2 h)
Study: 12428086
Drug: DX-9065a +
Normalized name: DX-890
DrugBank: Depelestat (DB17873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DX-9065a + ASA (pre-treatment)
Study: 12428086
Drug: Enoxaparin +
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin + ASA (1 mg/Kg s. c + 162 mg/day x 3 days)
Study: 9454525
Drug: Troglitazone 200
Normalized name: troglitazone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 200 mg/d
Study: 8578993
Drug: Caffeine (Cf,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (Cf, 50 mg/g of ointment or solution)
Study: 8578993
Drug: Interferon (IFN,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN, 5 x 10(4) IU/g)
Study: 7237896
Drug: Propranolol with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol with either diuretic
Study: 31507249
Drug: Other medications
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other medications for gout treatment
Study: 19159947
Drug: Cinnamon supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon supplementation (3 g day(‐1))
Study: 12151917
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium 20 mg
Study: 12151917
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium 40 mg
Study: 12151917
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 4 mg
Study: 7792126
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil (8 mg/kg/day twice daily)
Study: 31255371
Drug: Nutritional counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counseling plus a low-cost, intradialytic, protein-rich meal (200 mL milk plus two egg whites) thrice weekly for 3 months.
Study: 31074184
Drug: Acetazolamide 250–500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250–500 mg daily plus bumetanide 1–2 mg bid
Study: 31074184
Drug: High-dose loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose loop diuretics (bumetanide bid with daily dose twice the oral maintenance dose)
Study: 23286595
Drug: Proactive telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive telephone counseling with tailored self‐directed materials (including nicotine patches, if not contraindicated)
Study: 23286595
Drug: Tailored self‐directed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored self‐directed materials (including nicotine patches, if not contraindicated)